**Paritaprevir PK Fact Sheet**

**Details**

**Generic Name**  Paritaprevir  
**Trade Name**  Viekirax® (coformulated with ombitasvir and ritonavir)  
Viekirax® (coformulated with ombitasvir and ritonavir and copackaged with dasabuvir)  
**Class**  HCV NS3/4A inhibitor  
**Molecular Weight**  801.91 (dihydrate)  
**Structure**  

![Paritaprevir Structure](image)

**Summary of Key Pharmacokinetic Parameters**

Paritaprevir is available in a fixed-dose combination product with ombitasvir and ritonavir.

**Linearity/non-linearity**  
Paritaprevir exposures increased in a more than dose proportional manner and accumulation is ~1.5-fold.

**Steady state**  
Achieved after ~12 days of dosing.

**Plasma half life**  
~5.5 h

**Cmax**  
1470 (871) ng/ml (geometric mean (%CV)); 262 ng/ml (median based population PK analysis). Determined following administration of ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily with dasabuvir 250 mg twice daily.

**Cmin**  
Not stated

**AUC**  
6990 (96) ng.h/ml (geometric mean (%CV)); 2220 ng.h/ml (median based on population PK analysis). Determined following administration of ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily with dasabuvir 250 mg twice daily.

**Bioavailability**  
~50%

**Absorption**  
Relative to the fasting state, food increased the exposure (AUC) of ombitasvir by 211% with a moderate fat meal (approximately 600 Kcal, 20-30% calories from fat) and by 180% with a high fat meal (approximately 900 Kcal, 60% calories from fat). Paritaprevir should be administered with food.

**Protein Binding**  
~97-98.6%

**Volume of Distribution**  
16.7 L

**CSF:Plasma ratio**  
Not determined

**Semen:Plasma ratio**  
Not determined

**Renal Clearance**  
~9%

**Renal Impairment**  
No dose adjustment is required for patients with mild, moderate, or severe renal impairment. Administration has not been studied in patients on dialysis.

**Hepatic Impairment**  
No dose adjustment is required in patients with mild hepatic impairment (Child-Pugh A). The European product label does not recommend Viekirax® in patients with moderate hepatic impairment (Child-Pugh B) and contraindicates it in patients with severe hepatic impairment (Child-Pugh C). The US product label contraindicates Viekirax® in moderate to severe hepatic impairment (Child-Pugh B and C).
Paritaprevir PK Fact Sheet

Metabolism and Distribution

**Metabolised by**  
CYP3A4, CYP3A5 (minor)

**Inducer of**  
None expected.

**Inhibitor of**  
UGT1A1, OATP1B1, OATP1B3, OATP2B1, BCRP, P-gp

Does not inhibit OAT1 in vivo. Not expected to inhibit OCT1, OCT2, OAT3, MATE1, MATE2K at clinically relevant concentrations.

**Transported by**  
P-gp, BCRP, OATP1B1, OATP1B3

References

Unless otherwise stated (see below), information is from:

Viekirax® Summary of Product Characteristics, AbbVie Ltd.

Viekira Pak® US Prescribing Information, AbbVie Inc.